These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection. Woodle ES; Bruce DS; Josephson M; Cronin D; Newell KA; Millis JM; Piper JB; O'Laughlin R; Thistlethwaite JR Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115 [TBL] [Abstract][Full Text] [Related]
8. [Neurologic complications induced by the treatment of the acute renal allograft rejection with the monoclonal antibody OKT3]. Fernández O; Romero F; Bravo M; Burgos D; Cabello M; González-Molina M Neurologia; 1993 Oct; 8(8):277-80. PubMed ID: 8240843 [TBL] [Abstract][Full Text] [Related]
9. Prevention of the OKT3 first-dose syndrome by reduced initial dose followed by adjusted doses based on CD3 T-lymphocyte counts in pediatric renal graft recipients. Piatosa B; Grenda R; Prokurat S Transplant Proc; 1996 Dec; 28(6):3466-7. PubMed ID: 8962349 [No Abstract] [Full Text] [Related]